We found that ML385 aggravated the cisplatin-induced increase in ROS burden and ferroptosis by inhibiting the Nrf2-HMOX1 axis, restoring the sensitivity of resistant lung cancer cell lines to cisplatin. Here, HMOX1 is linked to lung cancer.